Data compiled by Redley Lamar · ChainSifter Intelligence
9Suppliers
1Customers
3Debt Items
0Related Chains
Source-Backed Evidence Depth
CytoDyn Inc. (CYDY) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
2Distinct source URLs
13High confidence
0.859Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
CytoDyn Inc. Suppliers
Ticker
Name
Confidence
Evidence
SAMSUNG-BIOLOGICS-CO-LTD
SAMSUNG-BIOLOGICS-CO-LTD
92%
On April 3, 2024, the Company and Samsung BioLogics Co., Ltd. ("Samsung") executed an agreement (the "Letter Agreement"), wherein the parties reached agreement for an orderly process for winding down…
YA-II-PN-LTD
YA-II-PN-LTD
92%
In January 2026, pursuant to a Standby Equity Purchase Agreement (the “SEPA”) entered into on November 3, 2025, between the Company and YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Y…
YORKVILLE
YORKVILLE
92%
In January 2026, pursuant to a Standby Equity Purchase Agreement (the “SEPA”) entered into on November 3, 2025, between the Company and YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Y…
MITCHELL-COHEN
MITCHELL-COHEN
90%
On January 10, 2024, the Company entered into an agreement with an executive services firm to engage Mitchell Cohen to provide financial and accounting services to the Company as an independent contractor
AMAREX
AMAREX
85%
The Company has agreed to pay 20% of its qualifying Revenue generated in each calendar year, if any, with such payments to be applied to the return of the Company's cash collateral in the amount of $…
JACOB-P-LALEZARI-M-D
JACOB-P-LALEZARI-M-D
85%
On January 26, 2024, the Company entered into an employment agreement with Jacob P. Lalezari, M.D., under which he is serving as the Company's Chief Executive Officer
THIRD-PARTY-GENERATIVE-ARTIFICIAL-INTELLIGENCE-A
THIRD-PARTY-GENERATIVE-ARTIFICIAL-INTELLIGENCE-A
85%
In March 2023, the Company entered into a joint development agreement with a third-party generative artificial intelligence ("AI") drug discovery and development company to develop one or more longer…
ALBERT-EINSTEIN-COLLEGE-OF-MEDICINE
ALBERT-EINSTEIN-COLLEGE-OF-MEDICINE
80%
In December 2023, the Company entered into a partnership with Albert Einstein College of Medicine and Montefiore Medical Center, located in New York
MONTEFIORE-MEDICAL-CENTER
MONTEFIORE-MEDICAL-CENTER
80%
In December 2023, the Company entered into a partnership with Albert Einstein College of Medicine and Montefiore Medical Center, located in New York
CytoDyn Inc. Customers
Ticker
Name
Confidence
Evidence
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
Table of Contents disputes could arise regarding ownership or use of those inventions. Other disputes may also arise relating to the performance or alleged breach of our agreements with third parties…
CytoDyn Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CYDY-DEBT-8993
Warrants outstanding: 127100000
90%
xbrl warrant detail from xbrl 2025-05-31.
CYDY-DEBT
Debt stack $2.3M
90%
Market cache reports total debt of $2.3M.
CYDY-DEBT-8994
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-05-31.
CytoDyn Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for CytoDyn Inc..
CytoDyn Inc. Ownership
Holder
Name
Confidence
Evidence
CYDY-OWNER-NBC-SECURITIES-INC
NBC SECURITIES, INC.
90%
13F overlay lists NBC SECURITIES, INC. as top holder; 9 tracked holders.
CytoDyn Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
